Skip to textbook content
Doctor’s PassportTextbook
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…

Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.

Neonatal jaundice and bilirubin treatment thresholds

Paediatrics and child health · UK scope · Sources checked 27 Aug 2026 · Clinical review pending

RapidFull
!
Jaundice in the first 24 hours or acute bilirubin encephalopathy

Visible jaundice before 24 hours is pathological until assessed, while lethargy, poor feeding, abnormal tone, high-pitched cry, apnoea, opisthotonus or seizures can indicate bilirubin neurotoxicity.

Action: Measure serum bilirubin within 2 hours for jaundice in the first 24 hours and obtain urgent medical review. Plot the result on the exact NICE gestation- and age-in-hours treatment chart, investigate haemolysis and infection, and start intensified phototherapy or arrange exchange transfusion when the relevant threshold or clinical encephalopathy indication is met. Do not wait for visible colour to worsen.

Synopsis

Assess jaundice by postnatal age and gestation, identify pathological and conjugated hyperbilirubinaemia, apply the correct NICE treatment graph or table, and prevent bilirubin encephalopathy without unnecessary treatment.

  • Jaundice reflects bilirubin deposition. Most newborn jaundice is unconjugated and transient, but timing, trajectory and the baby's condition determine risk.
  • Never use one universal bilirubin number: plot serum bilirubin against exact age in hours on the NICE graph or table for the baby's gestational age.
  • For jaundice before 24 hours, measure serum bilirubin within 2 hours and repeat every 6 hours until below the treatment threshold and stable or falling.
  • At 24 hours or later, measure bilirubin within 6 hours. Visual assessment alone must not be used to estimate concentration.
  • Use serum bilirubin for babies below 35 weeks and for all babies within the first 24 hours. After 24 hours at 35 weeks or more, transcutaneous measurement may screen.
  • If transcutaneous bilirubin exceeds 250 micromol/L, confirm with serum. Confirm with serum whenever the value is at or above the relevant treatment threshold.
  • First-line treatment above the phototherapy threshold is phototherapy with irradiance, surface area and eye protection delivered according to the device protocol.
  • Intensify phototherapy when bilirubin rises faster than 8.5 micromol/L/hour, is within 50 micromol/L of the exchange threshold after 72 hours, or fails to fall within 6 hours.
  • Stop phototherapy once serum bilirubin is at least 50 micromol/L below the relevant phototherapy threshold; check rebound serum bilirubin 12–18 hours later.
  • Use double-volume exchange transfusion when the exchange threshold is reached or acute bilirubin encephalopathy is present, while continuing intensified phototherapy.
  • In Rh or ABO haemolytic disease, consider IV immunoglobulin 500 mg/kg over 4 hours only when bilirubin continues rising faster than 8.5 micromol/L/hour despite intensified phototherapy.
  • Do not stop breastfeeding routinely. Assess attachment and intake, support frequent effective feeding and add expressed milk or formula only for a defined clinical indication.

Key red flags

Visible jaundice before 24 hours requires urgent serum bilirubin measurement and medical review because haemolysis, infection and other pathology are more likely.

Lethargy, poor suck, altered tone, high-pitched cry, retrocollis, opisthotonus, apnoea or seizures raises acute bilirubin encephalopathy and possible urgent exchange transfusion.

A bilirubin at or above the gestation- and age-specific exchange threshold is an emergency even if the baby currently looks well.

Pallor, rapidly rising bilirubin, positive direct antiglobulin test, hepatosplenomegaly or family history raises haemolysis, including Rh, ABO or red-cell enzyme disease.

Dark urine that stains the nappy, pale stools, poor growth or hepatomegaly suggests conjugated jaundice and cholestasis rather than physiological unconjugated jaundice.

Prolonged jaundice beyond 14 days in a term baby or 21 days in a preterm baby needs assessment; conjugated bilirubin above 25 micromol/L requires expert advice.

Investigation priorities

01
First-line: bilirubin measurementFirst stepFirst line

Quantify jaundice and determine treatment against the correct age- and gestation-specific threshold.

02
Reference standard: serum bilirubin plotted on the NICE treatment graph or tableReference standard

Decide phototherapy, intensified phototherapy, monitoring and exchange-transfusion action.

Management branches

Before 24 hoursUrgent pathological-jaundice pathway

Visible jaundice appears in the first day.

  1. Measure serum bilirubin within 2 hours and arrange urgent medical review.
  2. Plot the value against exact age and gestation and investigate haemolysis, sepsis and other causes.
  3. Repeat at least every 6 hours until below threshold and stable or falling, treating according to trajectory.

Key medicines

Intravenous human normal immunoglobulin500 mg/kg intravenously over 4 hours as an adjunct to continuous intensified phototherapy for Rh or ABO haemolytic disease when serum bilirubin continues rising faster than 8.5 micromol/L/hour. Use the selected product's neonatal infusion protocol.Confirm immune haemolytic disease and continue preparation for exchange transfusion. Monitor observations, urine output and infusion reactions; consider thrombosis, haemolysis, renal impairment and product-specific excipients. Dosing and preparation require senior neonatal and pharmacy oversight.
Open full textbook →Answer 2 questions
Sources and review status4 sources · checked 27 Aug 2026 · clinical review pending+
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.

  • NICE CG98 jaundice in newborn babies under 28 daysCurrent measurement methods, treatment graphs, phototherapy, IVIG, exchange and prolonged-jaundice recommendations.
  • NICE CG98 treatment threshold graphsOfficial gestation- and age-specific bilirubin graphs and implementation resources.
  • NHS newborn jaundiceUK overview of recognition, causes, testing and treatment.
  • NHS newborn blood spot screeningNational screening context relevant to prolonged jaundice and congenital hypothyroidism.

Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes

Authoring stateRapid draftClinical stateAwaiting reviewJurisdictionUnited Kingdom